Homepage
Medication Guide
Channels for Purchasing Tibsovo® (Ivosidenib)
Tibsovo® (Ivosidenib) is an oral targeted therapy indicated for IDH1 mutations. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of acute myeloid...
505
Wednesday, January 7th, 2026, 11:24
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET kinase inhibitor that has become an important targeted therapy for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 ...
508
Tuesday, January 6th, 2026, 10:15
What Are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that offers a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutati...
504
Tuesday, January 6th, 2026, 10:13
Dosage and Administration, Recommended Dose of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is the world’s first approved targeted therapy for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Rational administration of this medicat...
503
Tuesday, January 6th, 2026, 10:11
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is an oral kinase inhibitor that received its first marketing approval in the United States in 2020. This medication is primarily indicated for the treatment of specific types of...
505
Tuesday, January 6th, 2026, 10:08
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) harboring a specific genetic mutation, namely the MET exon 14 skipping mutation...
503
Tuesday, January 6th, 2026, 10:07
Enasidenib Dosage and Administration, Recommended Dose
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH2 mutation.Enasideni...
506
Monday, January 5th, 2026, 11:28
Side Effects of Enasidenib
Enasidenib is a targeted therapeutic agent for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.Side Effects of EnasidenibGastroi...
503
Monday, January 5th, 2026, 11:24
What are the Precautions for Enasidenib Use?
Enasidenib is an oral targeted therapy drug for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an isocitrate dehydrogenase 2 (IDH2) mutation. It was first approved f...
504
Monday, January 5th, 2026, 11:21
What are the indications for Enasidenib?
Enasidenib is an oral targeted therapy drug, marketed under the brand name IDHIFA®, which was first approved for marketing in the United States in 2017. It is an isocitrate dehydrogenase-2 (IDH2) inhi...
505
Monday, January 5th, 2026, 11:16
18 / 206
2053 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved